Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts

Group 1 - Nurix Therapeutics, Inc. (NRIX) is ranked second in a list of the 20 Best Biotech Stocks Under $20 to Buy Now [1] - Stifel raised the price target on NRIX to $35 from $33 while maintaining a Buy rating, highlighting 2026 as a crucial year for the company due to two registrational trials and additional Phase 1 updates [1][2] - Wells Fargo lowered the price target on NRIX to $29 from $30 but maintained an Overweight rating, indicating that shares are still considered cheap even without clinical triggers in 2026 [2] Group 2 - Nurix Therapeutics focuses on developing targeted protein modulation therapies using its proprietary DELigase platform, targeting ubiquitin signaling pathways for immunology and oncology [3] - The company aims to develop precision medicines to address unmet medical needs and improve patient outcomes [3]